Rein Therapeutics, Inc.
RNTX · XNASCIK 1420565fmd_028QB8W3FAS4H8B6EQ1BDKW7WJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2026, 43 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 10 | 14 | 18 | 18 | 11 | 17 | 18 | 4 | 14 | 11 |
| Total operating expenses | 18 | 23 | 32 | 30 | 20 | 27 | 28 | 16 | 65 | 51 |
| Operating income | (18) | (23) | (32) | (30) | (20) | (27) | (28) | (16) | (65) | (51) |
| Other non-operating income (expense) | – | – | – | 1 | (1) | 0 | 0 | 1 | 1 | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (2) | (1) |
| Net income | (18) | (23) | (32) | (29) | (27) | (26) | (27) | (16) | (63) | (50) |
| Net income to common shareholders | (18) | (23) | (32) | (29) | – | – | – | – | – | – |